| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jordi Colmenero | Q39185659 |
| P2093 | author name string | Gregory T Everson | |
| Steve Helmke | |||
| P2860 | cites work | Bile acid transporters: structure, function, regulation and pathophysiological implications | Q28027885 |
| The model for end-stage liver disease (MELD) | Q28290440 | ||
| Assessment of hepatic detoxification activity: proposal of an improved variant of the (13)c-methacetin breath test | Q28535385 | ||
| Liver fibrosis | Q29547449 | ||
| Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 | ||
| Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy | Q30414609 | ||
| Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease | Q30445138 | ||
| Sensitivity and specificity of plasma disappearance rate of indocyanine green as a prognostic indicator in acute liver failure | Q30939929 | ||
| Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? | Q33731308 | ||
| Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection | Q34154927 | ||
| Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. | Q34390093 | ||
| Plasma clearance of oral and intravenous cholic acid in subjects with and without chronic liver disease | Q34493993 | ||
| Review article: breath testing for human liver function assessment | Q35009519 | ||
| 13C-breath tests in hepatology (cytosolic liver function). | Q35812245 | ||
| Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial | Q35818743 | ||
| Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. | Q36903148 | ||
| Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. | Q37000501 | ||
| The management of portal hypertension: rational basis, available treatments and future options | Q37096337 | ||
| Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial | Q37156704 | ||
| 13C-breath tests for clinical investigation of liver mitochondrial function | Q37769578 | ||
| Functional aspects on the pathophysiology of portal hypertension in cirrhosis | Q38002725 | ||
| Clinical utility of 13C-liver-function breath tests for assessment of hepatic function. | Q38035198 | ||
| The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial | Q39101736 | ||
| Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. | Q39868791 | ||
| Plasma disappearance rate of indocyanine green: a tool to evaluate early graft outcome after liver transplantation | Q39902311 | ||
| Noninvasive assessment in vivo of hepatic drug metabolism in health and disease | Q40181732 | ||
| Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis | Q40229041 | ||
| Review article: quantitative tests of liver function. | Q40470988 | ||
| Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study | Q42176482 | ||
| Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). | Q42238599 | ||
| Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve | Q42438693 | ||
| Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection | Q42992285 | ||
| Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests | Q43158469 | ||
| Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis | Q43500799 | ||
| Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients | Q44527268 | ||
| Galactose elimination capacity as a prognostic marker in patients with severe acetaminophen-induced hepatotoxicity: 10 years' experience | Q44876914 | ||
| Quantitative liver function tests in donors and recipients of living donor liver transplantation | Q46947908 | ||
| Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis | Q47279523 | ||
| Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. | Q50480595 | ||
| The emerging role of transport systems in liver function tests. | Q50506029 | ||
| Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. | Q50575168 | ||
| Early noninvasive measurement of the indocyanine green plasma disappearance rate accurately predicts early graft dysfunction and mortality after deceased donor liver transplantation. | Q50581872 | ||
| K(ICG) value, a reliable real-time estimator of graft function, accurately predicts outcomes in adult living-donor liver transplantation. | Q50735889 | ||
| Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis. | Q50927954 | ||
| The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery. | Q51406116 | ||
| The value of serial determination of MEGX and hyaluronic acid early after orthotopic liver transplantation. | Q51560779 | ||
| Use of monoethylglycinexylidide as a liver function test in the liver transplant recipient. | Q51648622 | ||
| Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. | Q53918031 | ||
| Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis | Q56980632 | ||
| Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation* | Q60787070 | ||
| Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis | Q61763027 | ||
| Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases | Q68448591 | ||
| Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow | Q68450000 | ||
| Hepatic clearance of D-sorbitol. Noninvasive test for evaluating functional liver plasma flow | Q69056242 | ||
| First-order clearance of plasma galactose: the effect of liver disease | Q70451731 | ||
| [Lidocaine elimination and MEGX formation after oral lidocaine administration--a practicable test for assessment of quantitative liver function] | Q71547043 | ||
| PHYSIOLOGY OF DYE EXTRACTION BY THE LIVER: COMPARATIVE STUDIES OF SULFOBROMOPHTHALEIN AND INDOCYANINE GREEN | Q76625777 | ||
| Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt | Q80626785 | ||
| ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study | Q83947864 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 199-208 | |
| P577 | publication date | 2015-05-01 | |
| P1433 | published in | Current Opinion in Gastroenterology | Q15758708 |
| P1476 | title | Noninvasive assessment of liver function | |
| P478 | volume | 31 |
| Q40416496 | ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries |
| Q38683182 | Assessment of Haemodynamic Response to Nonselective Beta-Blockers in Portal Hypertension by Phase-Contrast Magnetic Resonance Angiography |
| Q91600205 | Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum |
| Q89968285 | Limitations of non-invasive tests for assessment of liver fibrosis |
| Q64107301 | Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment |
| Q26769609 | Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance |
| Q38975618 | Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic? |
| Q94475611 | Road to identifying endpoint biomarkers in the treatment of nonalcoholic steatohepatitis: are we there yet? |
| Q104748009 | The Within-Individual Reproducibility of the Disease Severity Index from the HepQuant SHUNT® Test of Liver Function and Physiology |
Search more.